Nurtec ODT vs Vyepti
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Nurtec ODT | US Vyepti | |
|---|---|---|
| Generic name | rimegepant | eptinezumab |
| Drug class | CGRP Receptor Antagonist | Anti-CGRP Monoclonal Antibody |
| Treats | Migraine (acute and preventive) | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Pfizer | Lundbeck |
| Year approved | 2020 | 2020 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $190M | — |
| Common side effects | Nausea, Stomach pain, Indigestion, Allergic reactions | Stuffy nose and sore throat, Allergic reactions, Fatigue |
Nurtec ODT
Frequently asked questions
Is Nurtec ODT or Vyepti better?
Neither is universally "better." Nurtec ODT (rimegepant) and Vyepti (eptinezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Nurtec ODT and Vyepti?
Nurtec ODT is a CGRP Receptor Antagonist made by Pfizer, while Vyepti is a Anti-CGRP Monoclonal Antibody made by Lundbeck. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Nurtec ODT has the larger estimated TV advertising budget of the two.